EG 427

📍 Paris, France🗓 Founded 2019👥 26 employees💰 Last funded Feb 2025
Biotechnology Research🌐 eg427.com
Website LinkedIn
At EG427 our unique, non-replicative Herpes Simplex Virus type 1 (HSV-1) based vector platform called HERMES, delivers, with pinpoint precision, highly selective, durable expression of disease modifying transgenes to address prevalent diseases in neurology. Our lead asset EG110A, for the treatment of neurogenic bladder dysfunction, has received IND clearance in June 2024 from the US FDA. Our revolutionary approach to the treatment of this disease aims at providing patients with a comprehensive, long-term solution to their bladder management, through a highly selective molecular biology approach overcoming the drawbacks of current standard of care. Our HQ and labs are in Paris, France, where we were founded in 2019. We have raised over USD 21 million, including from our Series A in 2021.
2
Total investors
1
Early stage
0
Mid stage
1
Late stage
2019
Founded

Investors

2 investors
All
Early stage
Mid stage
Late stage
Investor geography2 countries
United States
1
France
1
Frequently asked questions
Who invested in EG 427?
EG 427 has 2 investors on record on gritt.io, including 1 early-stage backers and 1 late-stage investors.
When did EG 427 last raise funding?
The most recent investment in EG 427 recorded on gritt.io was in February 2025.
When was EG 427 founded?
EG 427 was founded in 2019.
What industry is EG 427 in?
EG 427 operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is EG 427 based?
EG 427 is headquartered in Paris, France.